Ckd Bio (063160) - Total Liabilities
Based on the latest financial reports, Ckd Bio (063160) has total liabilities worth ₩172.83 Billion KRW (≈ $117.13 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how efficiently does Ckd Bio generate cash to assess how effectively this company generates cash.
Ckd Bio - Total Liabilities Trend (2008–2025)
This chart illustrates how Ckd Bio's total liabilities have evolved over time, based on quarterly financial data. Check Ckd Bio (063160) asset resilience to evaluate the company's liquid asset resilience ratio.
Ckd Bio Competitors by Total Liabilities
The table below lists competitors of Ckd Bio ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Invictus Energy Ltd
AU:IVZ
|
Australia | AU$1.45 Million |
|
Eureka Acquisition Corp Unit
NASDAQ:EURKU
|
USA | $1.53 Million |
|
MedFirst Healthcare Services lnc
TWO:4175
|
Taiwan | NT$5.70 Billion |
|
GLOSTER LTD (BSE)
NSE:GLOSTERLTD
|
India | Rs11.24 Billion |
|
SP Systems Co.Ltd
KQ:317830
|
Korea | ₩30.48 Billion |
|
Man Zai Industrial Co Ltd
TWO:4543
|
Taiwan | NT$767.12 Million |
|
Metrofile
JSE:MFL
|
South Africa | ZAC895.00 Million |
|
Siebert Financial Corp
NASDAQ:SIEB
|
USA | $669.88 Million |
Liability Composition Analysis (2008–2025)
This chart breaks down Ckd Bio's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Ckd Bio (063160) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.90 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.36 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.58 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ckd Bio's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ckd Bio (2008–2025)
The table below shows the annual total liabilities of Ckd Bio from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩172.83 Billion ≈ $117.13 Million |
+12.61% |
| 2024-12-31 | ₩153.48 Billion ≈ $104.01 Million |
-10.12% |
| 2023-12-31 | ₩170.76 Billion ≈ $115.72 Million |
+3.62% |
| 2022-12-31 | ₩164.79 Billion ≈ $111.68 Million |
+20.24% |
| 2021-12-31 | ₩137.05 Billion ≈ $92.88 Million |
+19.47% |
| 2020-12-31 | ₩114.71 Billion ≈ $77.74 Million |
+53.19% |
| 2019-12-31 | ₩74.88 Billion ≈ $50.75 Million |
+103.17% |
| 2018-12-31 | ₩36.86 Billion ≈ $24.98 Million |
-1.55% |
| 2017-12-31 | ₩37.44 Billion ≈ $25.37 Million |
-18.17% |
| 2016-12-31 | ₩45.75 Billion ≈ $31.00 Million |
+5.73% |
| 2015-12-31 | ₩43.27 Billion ≈ $29.32 Million |
+0.10% |
| 2014-12-31 | ₩43.22 Billion ≈ $29.29 Million |
-16.27% |
| 2013-12-31 | ₩51.62 Billion ≈ $34.99 Million |
-15.75% |
| 2012-12-31 | ₩61.28 Billion ≈ $41.53 Million |
-22.72% |
| 2011-12-31 | ₩79.29 Billion ≈ $53.73 Million |
+88.21% |
| 2010-12-31 | ₩42.13 Billion ≈ $28.55 Million |
-10.72% |
| 2009-12-31 | ₩47.18 Billion ≈ $31.98 Million |
+3.25% |
| 2008-12-31 | ₩45.70 Billion ≈ $30.97 Million |
-- |
About Ckd Bio
CKD Bio Corp. engages in the manufacturing and sale of pharmaceutical products in South Korea, Europe, Asia, the Middle East, and internationally. The company is also involved in real estate leasing and related ancillary; bio, cosmetics, and health functional food; property management; advertising communication; consulting, construction, and maintenance of corporate IT systems business. It also e… Read more